Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.88
0.00 (0.00%)
Aug 4, 2026, 1:14 PM CST

TPEX:4186 Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
364.79364.79354.17315.98318.24243.36
Revenue Growth
-1.90%3.00%12.09%-0.71%30.77%3.31%
Gross Profit
234.07234.07243.97198.46192.58124.79
Operating Income
37.3937.3944.844.277.61-102.79
Net Income
28.0528.0522.88-10.683.17-118.53
Earnings Per Share
0.310.310.25-0.120.04-1.32
EPS Growth
21.19%24.00%----

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
New Business Division
88.6888.6894.87---
Inspection Business Division
94.9294.9282.6175.8977.9462.94
Precise Medical Division
143.55143.55146.06200.91188.42130.03
Food Safety Business Division
37.6437.6430.6339.1951.8850.4
Total
364.79364.79354.17315.98318.24243.36

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
140.74140.74106.32182.14158.56159.7
Total Debt
264.12264.12229.64307.24279.7248.97
Net Cash (Debt)
-123.38-123.38-123.32-125.11-121.15-89.27
Net Cash Growth
------
Net Cash Per Share
-1.37-1.37-1.37-1.39-1.35-0.99

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
53.1353.138.3312.61-20.59-48.08
Capital Expenditures
-33.36-33.36-3.96-11.94-7.28-15.19
Free Cash Flow
19.7719.774.370.67-27.87-63.28
Free Cash Flow Growth
287.51%352.74%554.72%---

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
64.17%64.17%68.88%62.80%60.51%51.28%
Operating Margin
10.25%10.25%12.66%1.35%2.39%-42.24%
Pretax Margin
7.44%7.44%6.38%-3.60%1.16%-47.03%
Profit Margin
7.69%7.69%6.46%-3.38%1.00%-48.70%
FCF Margin
5.42%5.42%1.23%0.21%-8.76%-26.00%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
29.4835.7861.97-502.52-
P/FCF Ratio
41.6150.76324.592226.39--
PS Ratio
2.262.754.004.705.016.88